Key pathophysiologic mechanisms include: Mucosal barrier dysfunction: Impaired epithelial tight junctions allow bacterial translocation, triggering innate immune activation T-helper cell dysregulation: Predominantly Th1 and Th17 pathways drive chronic inflammation via TNF-, IL-12, IL-23 the basis for biologic therapy targets Transmural inflammation: Unlike UC (mucosal only), CD involves all layers: mucosa submucosa muscularis propria serosa Granuloma formation: Non-caseating granulomas are pathognomonic but present in only ~3050% of biopsies Fibrosis and stricture: Chronic inflammation activates myofibroblasts collagen deposition luminal narrowing obstructive symptoms Fistula formation: Transmural ulcers penetrate serosa form sinus tracts connect to adjacent bowel, bladder, vagina, or skin 7
Recovery During Body Recomposition Losing 15 to 20 percent of body weight involves significant structural remodeling
This knowledge has paved the way for new applications of senolytic drugs and the development of an innovative treatment method called One-Two Punch Therapy [72]
Available from: Seo IH, Lee YJ
More on sourcing below
Certain foods are more likely to exacerbate the gastrointestinal side effects associated with retatrutide, particularly during the dose-escalation phase when the body is still adjusting to the medication
